Skip to main content

Advertisement

Table 1 Baseline disease-related characteristics of rheumatoid arthritis patients: the ESCAPE RA study

From: Coronary arterial calcification in rheumatoid arthritis: comparison with the Multi-Ethnic Study of Atherosclerosis

Characteristic Tertiles of propensity for rheumatoid arthritis activity and severity
  All (n = 195) Tertile 1 (lowest, n = 65) Tertile 2 (middle, n = 65) Tertile 3 (highest, n = 65) P value
Disease characteristics      
   Disease duration (years) 9 (4 to 17) 4 (2 to 6) 8 (5 to 13) 21 (16 to 31) <0.001
   Rheumatoid factor or anti-cyclic citrullinated peptide seropositivity 152 (78.0) 37 (57.8) 58 (89.2) 53 (86.9) <0.001
   Disease Activity Score (for 28 joints – C-reactive protein) 3.57 (2.87 to 4.35) 3.18 (2.54 to 3.99) 3.57 (2.87 to 4.29) 4.00 (3.35 to 4.88) <0.001
   Health assessment questionnaire score (0 to 3) 0.63 (0.13 to 1.25) 0.13 (0 to 0.50) 0.75 (0.13 to 1.25) 1.38 (1.00 to 1.88) <0.001
   Total Sharp–van der Heijde Score 44 (16 to 116) 18 (5 to 36) 38 (20 to 68) 142 (83 to 221) <0.001
   Deformed + replaced joints 2 (0 to 7) 1 (0 to 2) 1 (0 to 3) 10 (4 to 14) <0.001
   C-reactive protein (mg/l) 2.46 (1.09 to 7.17) 1.7 (0.78 to 4.56) 2.6 (1.18 to 7.80) 2.96 (1.66 to 9.46) 0.004
Current treatment      
   Nonbiologic DMARDs only 94 (48.2) 37 (57.8) 29 (44.6) 25 (41.0) 0.19
   Biologic DMARD monotherapy 19 (9.7) 5 (7.8) 3 (4.6) 10 (16.4)  
   Nonbiologic + biologic DMARDs 70 (35.9) 20 (31.3) 28 (43.1) 22 (36.1)  
   No DMARDs 12 (6.2) 2 (3.1) 5 (7.7) 4 (6.6)  
   Glucocorticoids 75 (38.5) 23 (35.9) 20 (30.8) 31 (50.8) 0.06
   Nonsteroidal anti-inflammatory drugsa 126 (64.6) 40 (61.5) 41 (63.1) 45 (69.4) 0.67
  1. Characteristics expressed as median (interquartile range) or n (%). DMARD, disease-modifying antirheumatic drug; ESCAPE RA, Evaluation of Subclinical Cardiovascular Disease and Predictors of Events in Rheumatoid Arthritis. aIncludes both cyclooxygenase-2 selective and nonselective nonsteroidal anti-inflammatory drugs.